Details

Autor(en) / Beteiligte

• Otto, Sven
• Pautke, Christoph
• Van den Wyngaert, Tim
• Niepel, Daniela
• Schiødt, Morten

Titel

Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases

Ist Teil von

• Cancer treatment reviews, 2018-09, Vol.69, p.177-187

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• •Denosumab and bisphosphonates are associated with a certain risk of MRONJ.•This is most pertinent in the oncology setting as a result of the high doses used.•The risk must be managed before and during treatment by a multidisciplinary team.•Symptomatic relief of MRONJ can often be achieved with conservative treatment.•Surgery may be beneficial when mucosal healing is the ultimate goal of therapy or after failure of conservative treatment. Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal-related events [SREs] in patients with cancer and bone metastases) or possibly anti-angiogenic cancer treatment. While the implementation of preventive measures over recent years has reduced the risk of MRONJ in patients with bone metastases due to cancer, it is imperative to balance the risk of MRONJ against the beneficial effects of treatment with denosumab or bisphosphonates on the skeletal health of patients. Despite growing awareness of MRONJ within the medical community, there is a lack of large-scale, prospective clinical studies in this rapidly evolving field. Discussing preventive measures with patients and implementing them, both before and during treatment with bisphosphonates or denosumab, is the best option to reduce the risk of MRONJ. In particular, avoiding bone trauma and preventing and treating dental infections before and during denosumab or bisphosphonate therapy is crucial to minimize the risk of MRONJ. If MRONJ develops, conservative (non-surgical) treatment can provide symptom relief, but achieving mucosal closure remains challenging. When management of symptoms and mucosal healing are the ultimate goals of therapy, or after failure of conservative treatment, a surgical approach may be beneficial. This critical review, based on a best-evidence review of currently available literature, provides clear practical guidelines to help to prevent, manage and treat MRONJ. Overall, a multidisciplinary, pragmatic approach to MRONJ should be adopted, prioritizing patient’s quality of life and management of their skeletal malignant disease.